Trials / Completed
CompletedNCT01454531
An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 199 (actual)
- Sponsor
- ALK-Abelló A/S · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the tolerability of AVANZ.
Detailed description
To assess the tolerability of the up-dosing phase of AVANZ Phleum pratense. The frequency of patients with adverse reactions will be the study primary endpoint.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AVANZ Phleum pratense | AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2012-03-01
- Completion
- 2012-04-01
- First posted
- 2011-10-19
- Last updated
- 2015-03-06
- Results posted
- 2015-03-06
Locations
20 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT01454531. Inclusion in this directory is not an endorsement.